Seattle and Vancouver, November 6, 2025 : Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company, announced its third-quarter 2025 financial results and major progress in the development of cytisinicline, a novel therapy for nicotine dependence. The U.S. Food and Drug Administration (FDA) has officially accepted Achieve’s New Drug Application (NDA) for cytisinicline in smoking cessation, assigning a Prescription Drug User Fee Act (PDUFA) action date of June 20, 2026. The FDA also granted the Commissioner’s National Priority Voucher (CNPV) for cytisinicline in vaping cessation, making it one of only nine therapies selected under this prestigious designation.
Science Significance
Cytisinicline, a plant-derived alkaloid, targets nicotinic acetylcholine receptors to reduce nicotine cravings and withdrawal symptoms. Supported by data from over 2,000 participants in Phase 3 ORCA-2 and ORCA-3 trials, the therapy demonstrated statistically significant smoking abstinence rates versus placebo. Recent data published in Thorax also confirmed that cytisinicline enhanced quit rates among adults with Chronic Obstructive Pulmonary Disease (COPD), underscoring its efficacy and safety in diverse patient populations. The compound’s dual benefit in both smoking and e-cigarette cessation represents a scientific leap in addressing nicotine dependence, which remains a leading global cause of preventable death.
Regulatory Significance
The FDA’s NDA acceptance and assignment of a PDUFA date validate the robustness of Achieve’s clinical evidence. Additionally, the National Priority Voucher designation for vaping cessation not only accelerates regulatory engagement but also shortens FDA review timelines from 10–12 months to just 1–2 months, once the company completes its final submission. Cytisinicline also holds Breakthrough Therapy designation, reflecting its transformative potential in an area lacking FDA-approved vaping cessation therapies.
Business Significance
Advertisement
Achieve Life Sciences reported $48.1 million in cash reserves as of September 30, 2025, enabling continued regulatory and commercial preparation. The company recorded a net loss of $14.4 million for the quarter, consistent with late-stage R&D investments. With the appointment of Erik Atkisson as Chief Legal Officer, Achieve is strengthening its executive leadership as it moves toward potential commercialization in 2026. The anticipated approval could position Achieve as a market leader in nicotine-dependence therapeutics, addressing a global opportunity among the 29 million smokers and 17 million vapers in the U.S. alone.
Patients’ Significance
Cytisinicline offers new hope to millions of smokers and e-cigarette users who seek to overcome addiction. Unlike current nicotine replacement therapies that only address cravings temporarily, cytisinicline’s mechanism targets nicotine receptors directly, reducing both cravings and satisfaction derived from nicotine use. If approved, this would mark the first FDA-approved therapy for vaping cessation, addressing a critical public health gap that affects 1.6 million U.S. adolescents and millions of adult users who wish to quit.
Policy Significance
The FDA’s inclusion of cytisinicline in its National Priority Program emphasizes the government’s growing focus on tobacco harm reduction and addiction recovery. This initiative aligns with U.S. health policies aimed at reducing smoking-related mortality, supporting anti-vaping campaigns, and expanding access to innovative cessation therapies. The regulatory backing reinforces a national commitment to combat nicotine addiction as a chronic medical condition rather than a behavioral choice.
With its FDA NDA acceptance, National Priority Voucher award, and strong clinical results, Achieve Life Sciences is on the verge of reshaping the nicotine dependence treatment landscape. As the world anticipates the FDA’s June 2026 decision, cytisinicline stands poised to become the first dual-indication therapy for smoking and vaping cessation, offering a scientifically grounded, regulatory-endorsed, and commercially viable solution to one of today’s most pressing public health challenges.
Source: Achieve Life Sciences, Inc.. press release
